Richard, Zucara Therapeutics
ZT-01, a First in Class Drug to Prevent Hypoglycemia in Type 1 Diabetes
Zucara is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with insulin dependent diabetes. This pre-clinical technology is directed at regulating somatostatin in the pancreas which in Type 1 diabetes is not properly controlled. Our novel somatostatin receptor antagonist has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.
A robust preclinical data package has been generated with a prototype cyclic peptide compound, PRL-2903. In vivo efficacy has been confirmed through independent validation studies and ADME/T screening has been completed to select a lead drug candidate, ZT-01, for continued development.
Dr. Richard Liggins is the Chief Scientific Officer, and a co-founder of Zucara Therapeutics Inc. Prior to this, Dr. Liggins completed his PhD in Pharmaceutics at the University of British Columbia and was a formulation scientist at Angiotech Pharmaceuticals, developing novel formulations for systemic and controlled release/targeted delivery of multiple therapeutics. With 20 years of industrial drug development experience, Dr. Liggins has expertise in preclinical drug development and commercialization. He has developed a number of medical technologies and intellectual properties with multiple issued patents, in areas including peptide therapeutics, formulation technology and drug-device combinations. He is also a Senior Director in R&D at the Centre for Drug Research and Development and was a co-founder Sitka Biopharma Inc.